Dr. Thomas J. George
Claim this profileUniversity of Florida Health Science Center - Gainesville
Expert in Pancreatic Cancer
Expert in Cancer
35 reported clinical trials
106 drugs studied
About Thomas J. George
Education:
- Earned an MD (Doctor of Medicine).
Experience:
- Serves as the Director of the GI Oncology Program at the University of Florida, focusing on gastrointestinal malignancies and new cancer therapy development.
- Acted as the chair of the Medical Advisory Board to the State of Florida Department of Health and completed a 10-year term as the gubernatorial-appointed chair of the Florida Cancer Control and Research.
- Holds the position of Deputy Director at the UF Health Cancer Center.
- Board Certified in Hematology, Internal Medicine, and Oncology.
Area of expertise
1Pancreatic Cancer
Global LeaderStage IV
KRAS positive
Stage III
2Cancer
Global LeaderStage IV
Stage III
KRAS positive
Affiliated Hospitals
Clinical Trials Thomas J. George is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Talazoparib
for Advanced Cancer
This phase II trial studies if talazoparib works in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and has mutation(s) in deoxyribonucleic acid (DNA) damage response genes who have or have not already been treated with another PARP inhibitor. Talazoparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. All patients who take part on this study must have a gene aberration that changes how their tumors are able to repair DNA. This trial may help scientists learn whether some patients might benefit from taking different PARP inhibitors "one after the other" and learn how talazoparib works in treating patients with advanced cancer who have aberration in DNA repair genes.
Recruiting1 award Phase 219 criteria
More about Thomas J. George
Clinical Trial Related7 years of experience running clinical trials · Led 35 trials as a Principal Investigator · 12 Active Clinical TrialsTreatments Thomas J. George has experience with
- Nivolumab
- Pembrolizumab
- Olaparib
- Oxaliplatin
- Fluorouracil
- Binimetinib
Breakdown of trials Thomas J. George has run
Pancreatic Cancer
Cancer
Colorectal Cancer
Colon Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Thomas J. George specialize in?
Thomas J. George focuses on Pancreatic Cancer and Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are KRAS positive.
Is Thomas J. George currently recruiting for clinical trials?
Yes, Thomas J. George is currently recruiting for 12 clinical trials in Gainesville Florida. If you're interested in participating, you should apply.
Are there any treatments that Thomas J. George has studied deeply?
Yes, Thomas J. George has studied treatments such as Nivolumab, Pembrolizumab, Olaparib.
What is the best way to schedule an appointment with Thomas J. George?
Apply for one of the trials that Thomas J. George is conducting.
What is the office address of Thomas J. George?
The office of Thomas J. George is located at: University of Florida Health Science Center - Gainesville, Gainesville, Florida 32610 United States. This is the address for their practice at the University of Florida Health Science Center - Gainesville.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.